Clinical trials: Oxaliplatin, completed
Metastatic Pancreatic Ductal Adenocarcinoma
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer.
- Trial name
- NCT05630183
- Testing
- Botensilimab, Gemcitabine, Nab-paclitaxel
- Where
- 36 sites in United States
- Volunteers
- 81 people
- Sponsor
- Agenus Inc.
Locally Advanced Rectal Cancer
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
Phase II clinical trial, open-label, randomized, two arms, multicentre (possibly multinational). Academic, investigator initiated.
- Trial name
- AXEBEAM (NCT00828672)
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- 9 sites in Belgium
- Volunteers
- 84 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Gastric Cancer
Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)
This is a Phase 2, multi-cohort study to investigate safety, anti-tumor activity of the monoclonal antibody BGB A317 in combination with Anlotinib and standard chemotherapy as first-line treatment in Gastric, or Gastroesophageal…
- Trial name
- TALENT (NCT04963088)
- Testing
- BGB-A317, Anlotinib, Oxaliplatin
- Where
- China
- Volunteers
- 65 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Oxaliplatin in Treating Patients With Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have metastatic…
- Trial name
- NCT00004203
- Testing
- oxaliplatin
- Where
- 14 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Stomach Neoplasms, Cancer of Lymph Node
Lymph Node Metastasis in Extended Lymphadenectomy for Gastric Cancer From a CLASSIC Trial
The pattern of lymph node metastasis of the gastric cancer to each geographic lymph nose stations and the relation between each metastasis and survival are to be analyzed by retrospective review of medical records of who enrolled…
- Trial name
- NCT02298010
- Testing
- Capecitabine, oxaliplatin
- Volunteers
- 899 people
- Sponsor
- Seoul National University Hospital
Carcinoma of the Appendix, Primary Peritoneal Cavity Cancer
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix
This randomized phase II trial is studying the side effects and how well giving oxaliplatin or mitomycin C directly into the abdomen after surgery works in treating patients with tumors of the appendix.
- Trial name
- NCT01580410
- Testing
- mitomycin C, oxaliplatin, therapeutic conventional surgery
- Where
- 3 sites in United States
- Volunteers
- 136 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Colorectal Adenocarcinoma
Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)
To evaluate tolerance to and efficacy of bevacizumab in the treatment of MCRC in elderly patients, we propose a phase II randomised study comparing a chemotherapy + bevacizumab arm with a chemotherapy alone arm in the first-line…
- Trial name
- Prodige20 (NCT01900717)
- Testing
- LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified, LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Perihilar Cholangiocarcinoma
Biliary Drainage Plus HAIC in Locally Advanced pCCA
Biliary drainage and stent placement remains to be the main palliative treatment choice for advanced perihiliar cholangiocarcinoma (pCCA), and the life expectancy is only 4-6 months.
- Trial name
- NCT05024513
- Testing
- oxaliplatin and 5-fluorouracil, Biliary Drainage, Best Supportive Care
- Where
- China
- Volunteers
- 127 people
- Sponsor
- Peking University
Stage III Esophageal Squamous Cell Carcinoma, Stage II Esophageal Squamous Cell Carcinoma
Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy
Megestrol is a semisynthetic progesterone derivatives, have promote anabolic effects. Can improve appetite, weight gain, and improve bone marrow suppression, increase the tolerance put, chemotherapy, improve the quality of life…
- Trial name
- NCT02644408
- Testing
- Megestrol（Yining）, radiotherapy, chemotherapy
- Where
- China
- Volunteers
- 184 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Leukemia
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
Primary Objectives: 1. Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of oxaliplatin in combination with fludarabine, Ara-C and rituximab in patients with Richter's transformation, prolymphocytic…
- Trial name
- NCT00452374
- Testing
- Cytarabine, Fludarabine, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Cancer of Pancreas
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
The purpose of this research study is for the participant to give their own T cells (a type of blood cell in the body that can fight infections and possibly cancer) to them after they have been removed, grown in a lab, and then…
- Conditions
- Colorectal Cancer, Cancer of Pancreas, Pancreatic Neoplasm, Malignant Neoplasm of Large Intestine
- Trial name
- NCT01420874
- Testing
- FOLFOX6, EGFRBi armed ATC Infusions
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Colorectal Cancer
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer receiving chemotherapy may help doctors understand the effect of chemotherapy on biomarkers.
- Trial name
- NCT00559676
- Testing
- capecitabine, fluorouracil, irinotecan hydrochloride
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospital Regional Universitaire de Limoges
Metastatic Colorectal Cancer
1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.
The purpose of this study is to determinate progression free survival after 9 months of treatment.
- Trial name
- NCT00345696
- Testing
- Bevacizumab, Capecitabine, Oxaliplatine
- Where
- Spain
- Volunteers
- 32 people
- Sponsor
- Unidad Integral de Investigación en Oncología S.L.
Colorectal Cancer
Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer
Primary objective : To compare the combination of S-1 and oxaliplatin(SOX) to the combination of capecitabine and oxaliplatin(COX) therapy for advanced or metastatic colorectal carcinoma. Secondary objectives : 1.
- Trial name
- NCT00677443
- Testing
- S-1 & Oxaliplatin, Capecitabine & Oxaliplatin
- Where
- 11 sites in South Korea
- Volunteers
- 344 people
- Sponsor
- Samsung Medical Center
Advanced Gastric Cancer
A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China
This is a multi-center, prospective and observational clinical study. Eligible patients will accept generalized chemotherapy according to the investigator's assessment.
- Trial name
- NCT01472250
- Testing
- Clinical chemo-drugs
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Peking University
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma
This is a phase III, multi-Center, randomized, placebo-controlled trial to investigate the efficacy and safety of CS1001 in combination with Oxaliplatin and Capecitabine (CAPOX) chemotherapy in first-line subjects with…
- Trial name
- NCT03802591
- Testing
- CS1001 monoclonal antibody, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 479 people
- Sponsor
- CStone Pharmaceuticals
Previously Untreated Metastatic Colorectal Cancer
Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.
This is an exploratory study to compare activity and safety in 400 patients with previously untreated metastatic carcinoma of the colon treated with UFOX (a combination regimen of UFT® (Tegafur plus Uracil), Oxaliplatin, Folinic…
- Trial name
- FUTURE (NCT00439517)
- Testing
- UFOX + Cetuximab, FOLFOX4 + Cetuximab
- Where
- 57 sites in Argentina, Australia and 12 more
- Volunteers
- 302 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Gastric Cancer
Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis
Gastric cancer with para-aortic lymph node (PAN) involvement is regarded as advanced disease, and only chemotherapy is recommended from the guidelines.
- Trial name
- NCT02071043
- Testing
- Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Colorectal Cancer, Chemotherapy Effect
Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer
Chemoresistance remains an obstacle in treating people with metastatic colorectal cancer (mCRC). Studying samples of blood and tumor tissue in the laboratory from patients with mCRC receiving chemotherapy may help doctors…
- Conditions
- Metastatic Colorectal Cancer, Chemotherapy Effect, Biomarker
- Trial name
- NCT03532711
- Testing
- fluorouracil
- Volunteers
- 264 people
- Sponsor
- Fudan University
Pancreatic Adenocarcinoma
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
The purpose of this study is to assess the feasibility and efficacy outcomes of neoadjuvant modified FOLFIRINOX and postoperative gemcitabine in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT02749136
- Testing
- Preoperative modified FOLFIRINOX and postoperative gemcitabine
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Asan Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.